Skip to main content
Premium Trial:

Request an Annual Quote

Rubicon to Develop Cancer Markers for OncoMethylome

NEW YORK (GenomeWeb News) — OncoMethylome Sciences has tapped Rubicon Genomics to identify and analyze biomarkers that may lead to early cancer detection tests, Rubicon said today.
 
Under the collaboration, Rubicon will use its MethylPlex platform, which identifies multi-gene patterns of abnormal DNA methylation that arise during tumor development, to develop markers that predict the presence of cancer. The agreement also gives OncoMethylome an option to license markers that result from the collaboration.
 
Rubicon said it has already licensed a set of biomarkers to OncoMethylome resulting from a similar, earlier agreement.
 
Financial terms of the agreement were not released.

The Scan

Could Mix It Up

The US Food and Drug Administration is considering a plan that would allow for the mixing-and-matching of SARS-CoV-2 vaccines and boosters, the New York Times says.

Closest to the Dog

New Scientist reports that extinct Japanese wolf appears to be the closest known wild relative of dogs.

Offer to Come Back

The Knoxville News Sentinel reports that the University of Tennessee is offering Anming Hu, a professor who was acquitted of charges that he hid ties to China, his position back.

PNAS Papers on Myeloid Differentiation MicroRNAs, Urinary Exosomes, Maize Domestication

In PNAS this week: role of microRNAs in myeloid differentiation, exosomes in urine, and more.